COVID-19 Respiratory Distress and Antithrombotic Drugs in Subject's Habits

NCT04412473 | Unknown

• 1 other identifier: 7837
• Study Type: observational
• Target: 1,000
• Locations: 1 country
• Sites: 1

Brief Summary

Current management of VID-19 consists of oxygen support without specific treatment. Hospitalization may suddenly require delayed resuscitation. This evolution corresponds to an atypical acute respiratory distress syndrome (ARDS), the mechanism of which is poorly understood and difficult to predict. The general pathophysiology of ARDS, the vascular tropism of SARS-Cov2, the description of coagulopathy and numerous pulmonary artery thromboses in resuscitation and the encouraging investigation of antithrombotics in general ARDS

Conditions

Sars-CoV2

Keywords

Sars-CoV2; Covid-19; Antithrombotic treatments; ARDS; Hypoxemia; Thrombosis; Pulmonary arteries; Endothelial

Outcome Measures

Primary Outcomes (1)

• Analysis of Respiratory Distress and Antithrombolytic Therapy in Patients with covid19

  1 month

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult Partients hospitalised in HUS or GHRMSA for COVID-19 with diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record

You may qualify if:

• Major Subject (≥18 years)
• Subject hospitalised in HUS or GHRMSA for COVID-19
• The diagnosis COVID-19 confirmed by smear or evoked by CT scan or chest X-ray without a differential diagnosis retained in the medical record
• Subjects who, after being informed, do not wish to have their data reused for the purposes of this research

You may not qualify if:

• Subject who expressed opposition to participating in the study
• Subject under guardianship or trusteeship
• Subject under safeguard of justice
• Patient hospitalized in a geriatric service or in a ward not labeled COVID (surgery, oncology,...) or in a short-term hospitalization unit without transfer to another service.
• Serious patient on admission to the emergency room and recused from resuscitation.

Sponsors & Collaborators

• University Hospital, Strasbourg, France: lead

Study Sites (1)

Service Médecine Intensive et Réanimation

Strasbourg, 67091, France

RECRUITING

MeSH Terms

Conditions

COVID-19; Hypoxia; Thrombosis

Condition Hierarchy (Ancestors)

Pneumonia, Viral; Pneumonia; Respiratory Tract Infections; Infections; Virus Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Lung Diseases; Respiratory Tract Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms; Embolism and Thrombosis; Vascular Diseases; Cardiovascular Diseases

Central Study Contacts

Vincent CASTELAIN, MD, PhD

CONTACT

33 3 88 12 82 69; Vincent.CASTELAIN@chru-strasbourg.fr

Saïd CHAYER, PhD, HDR

CONTACT

33 3 88 11 66 90; said.chayer@chru-strasbourg.fr

Study Design

• Study Type: observational
• Observational Model: CASE ONLY
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: May 27, 2020
• First Posted: June 2, 2020
• Study Start: April 30, 2020
• Primary Completion: June 1, 2021
• Study Completion: June 1, 2021
• Last Updated: January 11, 2021

Record last verified: 2020-05

Locations

FR (1)